Please login to the form below
How to make an impact at a virtual congress
As hard as congress organisers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real opportunity to innovate, leverage the benefits of digital channels, and approach congresses in a completely different way.
The pharmaceutical industry has long relied on congresses to build relationships with customers and to showcase the latest data and information on new additions to the pipeline. However, COVID-19 has changed the congress experience significantly. Social distancing and travel restrictions have forced congress organizers to make a tough decision between canceling events or re-formatting for a remote audience.
As hard as congress organizers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real opportunity to innovate, leverage the benefits of digital channels, and approach congresses in a completely different way.
More competition than ever before
The pharmaceutical industry has long relied on congresses to build relationships with customers and to showcase the latest data and information on new additions to the pipeline. However, COVID-19 has changed the congress experience significantly. Social distancing and travel restrictions have forced congress organizers to make a tough decision between canceling events or re-formatting for a remote audience.
As hard as congress organizers try, replicating the congress experience on a virtual platform is difficult. Rather than trying to replicate the in-person congress experience, the industry has a real opportunity to innovate, leverage the benefits of digital channels, and approach congresses in a completely different way.
More competition than ever before
Virtual congresses are different from physical congresses and bring with them a new set of challenges. Firstly, delegate behaviour differs. When a healthcare professional attends a physical congress, they commit the entire day to the event. At a virtual congress, they can log on or off at a time that suits them, and they can become distracted by work or by their home life. So, you are competing with more than just your competitors for attendees’ time.
During the ASCO 2020 Annual Meeting, just 16% of respondents visited virtual booths or exhibits from pharmaceutical companies. Among those who did visit, more than half spent significantly less time visiting the stands than when attending an in-person congress. With no congress hall to walk around the delegates may not have felt inspired to visit the exhibits.
We have more patience in the physical world. Slow loading times, poor user experience, content that is too personalized and perceived as invasive, poorly written content, and content that is not personalized enough, all leads users to click away from a website without a second thought.
These challenges change the essence of the congress experience. However, virtual congresses also provide new ways of engaging customers and develop a captive digital audience. So, how can pharmaceutical companies create an impactful virtual congress experience?
DOWNLOAD THE REST OF THE ARTICLE HERE
Company Details
Blue Latitude Health
Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom
Latest content on this profile
- Three strategies for managing loss of exclusivity successfully
- Consultant, Claire Taylor explains why you should be strategically planning your LOE strategy years in advance.
Blue Latitude Health
- What does the future hold for Medical Affairs?
- Lori Lush, Head of Fishawack Medical, reveals why she’s driven to tell impactful scientific stories, the benefits of cross-functional collaboration, and the trends she predicts for the next five years.
Blue Latitude Health
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the life sciences industry can do to rebuild trust.
Blue Latitude Health
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and Senior Consultant Craig Moore explore the benefits of using real-world evidence and the common pitfalls life science companies should avoid.
Blue Latitude Health
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of this lost time for patients?
Blue Latitude Health
- Unpacking rare diseases in the first edition of Delta magazine
- Fishawack Health launches Delta magazine with a deep dive into rare disease commercialization
Blue Latitude Health
